Since many Her2 + cancers occur in ductal areas, and our results did not exclude the suitability of IgE and IgA isotype variants, the availability of such Trastuzumab/Pertuzumab IgE and IgA variants may be ideal for such localities. This evidence concerns the gene ERBB2 and cancer.